Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer
出版年份 2021 全文链接
标题
Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer
作者
关键词
-
出版物
Cancers
Volume 13, Issue 19, Pages 4854
出版商
MDPI AG
发表日期
2021-09-29
DOI
10.3390/cancers13194854
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
- (2021) Navid Sobhani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Osteopontin accelerates the development and metastasis of bladder cancer via activating JAK1/STAT1 pathway
- (2020) Na Zhang et al. Genes & Genomics
- TRIM66 promotes malignant progression of prostate carcinoma through the JAK/STAT pathway
- (2020) Hongwen Cao et al. FEBS Open Bio
- Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC
- (2020) Kelvin Anderson et al. Frontiers in Immunology
- Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial–Mesenchymal Transition
- (2020) Wook Jin Cells
- Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer
- (2020) Konrad H. Stopsack et al. CLINICAL CANCER RESEARCH
- Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
- (2020) Bastien Nguyen et al. EUROPEAN UROLOGY
- Microbiome analyses of blood and tissues suggest cancer diagnostic approach
- (2020) Gregory D. Poore et al. NATURE
- Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
- (2020) Holger H. H. Erb et al. PLoS One
- STAT3 Contributes to Radioresistance in Cancer
- (2020) Xuehai Wang et al. Frontiers in Oncology
- STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
- (2020) Giacomo Canesin et al. Scientific Reports
- Endothelial-to-Mesenchymal Transition in Cancer
- (2020) Nicolas Clere et al. Frontiers in Cell and Developmental Biology
- JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma
- (2019) Soheila Dolatabadi et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular landmarks of tumor hypoxia across cancer types
- (2019) Vinayak Bhandari et al. NATURE GENETICS
- The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis
- (2019) Wenjuan Mei et al. Cancers
- MTMR2 promotes invasion and metastasis of gastric cancer via inactivating IFNγ/STAT1 signaling
- (2019) Lei Jiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cancer‐bone microenvironmental interactions promotes STAT3 signaling
- (2019) Veronica M. Henderson et al. MOLECULAR CARCINOGENESIS
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Upregulation of Complement Factor H by SOCS-1/3–STAT4 in Lung Cancer
- (2019) Yeon-Hee Yoon et al. Cancers
- STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice
- (2019) Boutillon et al. Cancers
- Enzalutamide Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors
- (2019) Vindhya Udhane et al. MOLECULAR CANCER THERAPEUTICS
- STAT1 inhibits T‐cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma
- (2019) Nathan Ryan et al. INTERNATIONAL JOURNAL OF CANCER
- A NF-ĸB-Activin A signaling axis enhances prostate cancer metastasis
- (2019) Lanpeng Chen et al. ONCOGENE
- The potential and controversy of targeting STAT family members in cancer
- (2019) Yannick Verhoeven et al. SEMINARS IN CANCER BIOLOGY
- JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
- (2019) Katie L. Owen et al. Cancers
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy
- (2018) Alison M. Taylor et al. CANCER CELL
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
- (2018) Li Ding et al. CELL
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- (2018) Francisco Sanchez-Vega et al. CELL
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- (2018) Katherine A. Hoadley et al. CELL
- STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair
- (2018) Cristina Maranto et al. CLINICAL CANCER RESEARCH
- Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression
- (2018) Shancheng Ren et al. EUROPEAN UROLOGY
- Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
- (2018) Jun Luo et al. EUROPEAN UROLOGY
- Profiling Prostate Cancer Therapeutic Resistance
- (2018) Cameron Wade et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer
- (2018) Lan Zhang et al. Molecular Medicine Reports
- Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
- (2018) LiJun Xu et al. Molecular Oncology
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
- (2018) Qingsong Gao et al. Cell Reports
- Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
- (2018) Kyle Ellrott et al. Cell Systems
- Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
- (2018) Adam Sharp et al. JOURNAL OF CLINICAL INVESTIGATION
- MicroRNA‑135a induces prostate cancer cell apoptosis via inhibition of STAT6
- (2018) Bin Xu et al. Oncology Letters
- Expression of STAT3 in Prostate Cancer Metastases
- (2017) Nicholas Don-Doncow et al. EUROPEAN UROLOGY
- Genomic hallmarks of localized, non-indolent prostate cancer
- (2017) Michael Fraser et al. NATURE
- Cancer stem cells revisited
- (2017) Eduard Batlle et al. NATURE MEDICINE
- An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis
- (2017) L Zhao et al. ONCOGENE
- Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT
- (2017) Qiuli Liu et al. Cell Death & Disease
- The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
- (2017) G Nappo et al. Oncogenesis
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade
- (2017) Sanjay Varikuti et al. OncoImmunology
- The molecular and cellular origin of human prostate cancer
- (2016) John R. Packer et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- The mouse prostate: a basic anatomical and histological guideline
- (2016) Daniel S.M. Oliveira et al. Bosnian Journal of Basic Medical Sciences
- Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
- (2016) Daniela Verzella et al. CURRENT DRUG TARGETS
- The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer
- (2016) Giacomo Canesin et al. EUROPEAN UROLOGY
- STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases
- (2016) Tiziana Lorenzini et al. JOURNAL OF LEUKOCYTE BIOLOGY
- SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells
- (2016) F. Handle et al. MOLECULAR CANCER RESEARCH
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
- (2015) Pooja G. Talati et al. AMERICAN JOURNAL OF PATHOLOGY
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Altered STAT4 Isoform Expression in Patients with Inflammatory Bowel Disease
- (2015) Rukhsana Jabeen et al. INFLAMMATORY BOWEL DISEASES
- Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence
- (2015) Sophia Hatziieremia et al. MOLECULAR CARCINOGENESIS
- Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma
- (2015) Gang Wang WORLD JOURNAL OF GASTROENTEROLOGY
- miR-135b inhibits tumour metastasis in prostate cancer by targeting STAT6
- (2015) NING WANG et al. Oncology Letters
- STAT3 regulated ARF expression suppresses prostate cancer metastasis
- (2015) Jan Pencik et al. Nature Communications
- Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
- (2015) Xiaohong Tian et al. Frontiers in Pharmacology
- Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer
- (2015) D. T. Hoang et al. MOLECULAR CANCER THERAPEUTICS
- PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells
- (2015) Martin Puhr et al. Oncotarget
- Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer
- (2015) Zhiqiang Han et al. Oncotarget
- Multiple regulation pathways and pivotal biological functions of STAT3 in cancer
- (2015) Jie Yuan et al. Scientific Reports
- Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice
- (2015) Jorge M. Blando et al. NEOPLASIA
- High STAT4 Expression is a Better Prognostic Indicator in Patients with Hepatocellular Carcinoma After Hepatectomy
- (2014) Gizachew Yismaw Wubetu et al. ANNALS OF SURGICAL ONCOLOGY
- MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6)
- (2014) Dachuang Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- AR function in promoting metastatic prostate cancer
- (2014) Michael A. Augello et al. CANCER AND METASTASIS REVIEWS
- Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6-Induced Experimental Prostate Cancer Metastases Formation
- (2014) L. Gu et al. MOLECULAR CANCER THERAPEUTICS
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression
- (2014) R Jin et al. ONCOGENE
- Copy number alteration burden predicts prostate cancer relapse
- (2014) H. Hieronymus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development
- (2014) Elias A. El-Habr et al. VIRCHOWS ARCHIV
- The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
- (2014) Jennifer Bishop et al. Cancers
- STAT5A/B Gene Locus Undergoes Amplification during Human Prostate Cancer Progression
- (2013) Bassem R. Haddad et al. AMERICAN JOURNAL OF PATHOLOGY
- JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
- (2013) P. Kroon et al. CANCER RESEARCH
- Punctuated Evolution of Prostate Cancer Genomes
- (2013) Sylvan C. Baca et al. CELL
- PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling
- (2013) M Conley-LaComb et al. Molecular Cancer
- Interleukin-6 and Oncostatin-M Synergize with the PI3K/AKT Pathway to Promote Aggressive Prostate Malignancy in Mouse and Human Tissues
- (2013) Daniel A. Smith et al. MOLECULAR CANCER RESEARCH
- AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
- (2013) E. R. Plimack et al. ONCOLOGIST
- Activation of NF-kappa B Signaling Promotes Growth of Prostate Cancer Cells in Bone
- (2013) Renjie Jin et al. PLoS One
- Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells
- (2013) T. Stoyanova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells
- (2013) Chengfei Liu et al. PROSTATE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
- (2012) Martin Puhr et al. AMERICAN JOURNAL OF PATHOLOGY
- A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
- (2012) Gary Hudes et al. INVESTIGATIONAL NEW DRUGS
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer
- (2012) Jordi Codony-Servat et al. PROSTATE
- Detection of STAT2 in early stage of cervical premalignancy and in cervical cancer
- (2012) Zeng Liang et al. Asian Pacific Journal of Tropical Medicine
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo
- (2011) C. Thomas et al. MOLECULAR CANCER THERAPEUTICS
- The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
- (2011) Jayaprakash Karkera et al. PROSTATE
- New and emerging agents for the treatment of castration-resistant prostate cancer
- (2011) Celestia S. Higano et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Signal Transducer and Activator of Transcription 6 (STAT6) Is a Novel Interactor of Annexin A2 in Prostate Cancer Cells
- (2010) Susobhan Das et al. BIOCHEMISTRY
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- STAT2 Contributes to Promotion of Colorectal and Skin Carcinogenesis
- (2010) A. M. Gamero et al. Cancer Prevention Research
- Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
- (2010) T. B. Dorff et al. CLINICAL CANCER RESEARCH
- Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo
- (2010) Lei Gu et al. ENDOCRINE-RELATED CANCER
- Induction of Clusterin by AKT--Role in Cytoprotection against Docetaxel in Prostate Tumor Cells
- (2010) B. Zhong et al. MOLECULAR CANCER THERAPEUTICS
- Protein kinase Cɛ mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2 and ERK1/2)
- (2010) M H Aziz et al. ONCOGENE
- Identifying significant genetic regulatory networks in the prostate cancer from microarray data based on transcription factor analysis and conditional independency
- (2009) Hsiang-Yuan Yeh et al. BMC Medical Genomics
- Inflammation and Cancer: IL-6 and STAT3 Complete the Link
- (2009) Jacqueline Bromberg et al. CANCER CELL
- Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
- (2009) Sergei I. Grivennikov et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells
- (2008) S.-H. Tan et al. CANCER RESEARCH
- The Nuclear Factor- B Pathway Controls the Progression of Prostate Cancer to Androgen-Independent Growth
- (2008) R. J. Jin et al. CANCER RESEARCH
- Transcription Factor Signal Transducer and Activator of Transcription 5 Promotes Growth of Human Prostate Cancer Cells In vivo
- (2008) A. Dagvadorj et al. CLINICAL CANCER RESEARCH
- The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells
- (2008) Marina Zemskova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions
- (2008) Richard Birnie et al. GENOME BIOLOGY
- Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3
- (2007) Rebecka Hellsten et al. PROSTATE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started